Archis Pharma

Dr. Kovi has over 20 years of experience in diversified areas of pharmaceutical R&D, and Drug Development processes. He currently serves as the President and CEO of Apicore US LLC where he was able to achieve significant revenue growth year over year, mainly by the combination of commercializing the API products world-wide and achieving ANDA develo... pment partnership project deals with multiple established medium and big pharma partners. In this role, Dr. Kovi was primarily responsible for identifying new molecules and securing partnerships for aggressively moving up the value chain by embarking on New Drug Applications for the developments of New Drugs. Prior to Apicore, Dr Kovi had successful stints in Branded as well as generic Pharmaceuticals in India, as a scientist at Torrent Research Centre and Orchid Pharmaceuticals, before moving to the US where he worked as a Scientist at Biogen and as an Investigator at Vertex Pharmaceuticals Inc. Dr. Kovi was also successful in securing investments of approximately $23 million USD from brand companies and investing firms as an equity and debt combination into Apicore. In October 2017, Apicore US LLC was sold to a large pharmaceutical company, which resulted in significant ROI to the shareholders and employees. Dr Kovi, has also founded RK Pharma Inc, a vertically integrated Pharmaceutical group, with expertise in manufacturing Key Starting Materials, Intermediates, APIs and finished dosage forms. Recently RK Pharma Inc leased Pfizers Pearl River manufacturing facility to manufacture finished dosage forms and, setup Archis Pharma LLC to commercialize the groups and other in-licensed products. Dr. Kovi received his Masters of Pharmacy degree from the Birla Institute of Technology and Sciences Pilani, India. He received his Ph.D. from the M.S University in Vadodara, India. Dr. Kovi has published several research papers and has numerous patents in his name.Read More